NTRK1 and pancreatic ductal adenocarcinoma: NTRK gene fusions are known to be oncogenic drivers in pancreatic ductal adenocarcinoma (PDAC), thus providing a potential target for therapy with tropomyosin receptor kinase (TRK) inhibitors.